Brooks Laboratories Profit & Loss Annual

BSE: 533543 | NSE: BROOKS | ISIN: INE650L01011 | Sector: Major Drugs

69.81 -0.65 (-0.92%)Updated : 09 Oct 2026

Research on

Interim Data

Annual Data

Fiscal Period	2026	2025	2024	2023
Period End Date	Mar 26	Mar 25	Mar 24	Mar 23
Total Operating Expense	80.09	79.13	78.04	96.25
Other Net	0.26	0.17	0.57	-0.15
Diluted Weighted Average Shares	2.95	2.68	2.56	2.49
Gain( Loss)on Saleof Assets	0.28	0.01	-	0.00
Depreciation/ Amortization	1.59	1.60	1.77	7.03
Operating Income	5.65	3.43	1.44	-33.05
Net Income	24.58	-9.97	-19.59	-20.90
Income Availableto Com Excl Extra Ord	24.58	-9.97	-19.59	-20.90
Other Operating Expenses Total	1.18	1.32	1.23	4.22
Net Income Before Taxes	24.58	-9.79	-19.57	-38.38
Net Income After Taxes	24.58	-9.97	-19.59	-31.05
Income Availableto Com Incl Extra Ord	24.58	-9.97	-19.59	-20.90
Costof Revenue Total	54.37	57.10	59.07	57.01
Gross Profit	31.37	25.45	20.41	6.20
Interest Inc( Exp) Net- Non- Op Total	18.39	-13.40	-21.58	-5.18
Unusual Expense( Income)	0.00	-0.09	0.00	-0.36
Diluted Net Income	24.58	-9.97	-19.59	-20.90
Provisionfor Income Taxes	0.00	0.18	0.03	-7.32
period Type	-	-	-	-
Net Income Before Extra Items	24.58	-9.97	-19.59	-20.90
Total Revenue	85.74	82.56	79.49	63.20
period Length	12.00	12.00	12.00	12.00
Revenue	85.74	82.56	79.49	63.20
Selling/ General/ Admin Expenses Total	22.95	19.20	15.97	28.35
Diluted Normalized EPS	8.25	-3.74	-7.65	-8.47
Diluted EPS Excluding Extra Ord Items	8.35	-3.72	-7.65	-8.38
Minority Interest	-	-	0.00	10.15